Paid Clinical Trials in Marshfield, WI
As of September 2026, 99 paid clinical trials are recruiting in Marshfield, Wisconsin. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Marshfield offers studies at sites including Marshfield Medical Center-Marshfield for conditions such as Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Marshfield
Trials by drug in Marshfield
Filter results
97 clinical trials
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Top Research Study Locations in Marshfield
Researchers run research studies in Marshfield, WI at 13 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Marshfield Medical Center-Marshfield | Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8 | 80 |
| Marshfield Clinic | Birth Defect, Brain Injury, Cardiovascular Diseases | 4 |
| Marshfield Medical Center - Marshfield | Aortoiliac Occlusive Disease, Cutaneous Melanoma, Stage II, Healthy | 4 |
| Marshfield Clinic Health System | Cancer, General Research Use, Lumbar Spinal Stenosis | 2 |
| Marshfield Clinic Research Institute | Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III | 2 |
| Marshfield Medical Center | Leiomyosarcoma, Liposarcoma, Retroperitoneal Sarcoma | 2 |
| Local Institution - 0421 | Non-Small Cell Lung Cancer (NSCLC) | 1 |
| Marshfield Clinic Research Foundation | Bardet-Biedl Syndrome | 1 |
| Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc | Measles, Measles-Mumps-Rubella+Chickenpox Vaccine, Mumps | 1 |
| Marshfield Clinical Research Institute | Coronary Artery Disease Progression, Coronary Artery Disease Risk Factors Multiple, Premature Atherosclerosis | 1 |
| Marshfield Hospital | Aortoiliac Occlusive Disease | 1 |
| Marshfield Medical Center - Marshfield-(Hospital) | Healthy | 1 |
| Tenax Investigational Site | Pulmonary Hypertension Associated With HFpEF | 1 |
Active & Upcoming Studies in Marshfield (2026)
Recruiting trials in Marshfield grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (71 active studies)
- A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) · Phase 3 · Bristol-Myers Squibb
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · Phase 3 · NRG Oncology
Cardiovascular (4 active studies)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis · Phase 3 · Duke University
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
Vaccines (1 active study)
Diabetes & metabolic (1 active study)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
Neurology & pain (1 active study)
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study · Phase 4 · Mayo Clinic
Common conditions studied in Marshfield
- Stage IV Lung Cancer AJCC v8 (5 active studies)
- Stage IIIB Lung Cancer AJCC v8 (4 active studies)
- Stage IVB Prostate Cancer AJCC v8 (4 active studies)
- Acute Myeloid Leukemia (3 active studies)
- Advanced Lung Non-Small Cell Carcinoma (3 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (3 active studies)
Leading research sponsors in Marshfield
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
- NRG Oncology
- Children's Oncology Group
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Marshfield?
There are approximately 99 recruiting clinical trials in Marshfield, Wisconsin listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Marshfield pay participants?
Most recruiting trials in Marshfield compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Marshfield?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Marshfield?
The most common conditions under active study in Marshfield include Stage IV Lung Cancer AJCC v8 (5), Stage IIIB Lung Cancer AJCC v8 (4), Stage IVB Prostate Cancer AJCC v8 (4), Acute Myeloid Leukemia (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Marshfield?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Marshfield on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Marshfield?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Marshfield?
Recruiting research sites in Marshfield include Marshfield Medical Center-Marshfield, Marshfield Clinic, Marshfield Medical Center - Marshfield, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Marshfield right now?
The largest active categories in Marshfield are Cancer & tumors (71), Cardiovascular (4), Vaccines (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.